Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02647424
Other study ID # HKU-VL-LCC
Secondary ID
Status Recruiting
Phase N/A
First received December 29, 2015
Last updated October 26, 2016
Start date December 2015
Est. completion date December 2017

Study information

Verified date October 2016
Source The University of Hong Kong
Contact Vivian Lee, MBBS, MRCOG
Phone 22553400
Email v200lee@hku.hk
Is FDA regulated No
Health authority Hong Kong: Ethics Committee
Study type Interventional

Clinical Trial Summary

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies, affecting 5% to 10% of women of reproductive age. Women with PCOS suffer from anovulatory infertility. Following lifestyle modification with weight reduction in obese PCOS women, clomifene citrate (CC) is considered the first line treatment for ovulation induction (OI) in these women. 75-80% of women will ovulate after CC administration. However, there is a discrepancy between the ovulation rate and pregnancy rate, which was reported to be 22% per each ovulating cycles after CC. Other alternatives, including gonadotropin injections and laparoscopic ovarian drilling, carried different disadvantages, such as costly treatment and risks of ovarian hyperstimulation syndrome and multiple pregnancy rate in gonadotrophin therapy and surgical risks and risk of ovarian failure in surgical treatment.

The use of aromatase inhibitor, letrozole (LTZ), in reproductive medicine started in 2001. After this publication, there have been many groups of investigators studying the use of LTZ either in OI or ovarian stimulation in IVF cycles. A large multicentre randomized trial reported a significantly higher ovulation rate and live-birth rate comparing LTZ with CC. In majority of the publications, the multiple pregnancy rate was lower in LTZ group than in CC group. This can be attributed to the higher chance of monofollicular development after LTZ compared with CC. However, there is no information comparing the hormonal profile and follicular development after letrozole and CC.

Mild ovarian stimulation using LTZ or CC in conjunction with intrauterine insemination is commonly offered to ovulatory women with unexplained infertility, minimal endometriosis or mild factor to improve the pregnancy rate. There is again no information comparing the hormonal profile and follicular development after letrozole and CC in ovulatory women.

The aim of this study is to compare the hormonal profile after the use of LTZ and CC in anovulatory PCOS women and ovulatory women with unexplained subfertility. The hypothesis is that the FSH risk after LTZ is shorter than that of CC.


Description:

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies, affecting 5% to 10% of women of reproductive age. Women with PCOS suffer from anovulatory infertility. Following lifestyle modification with weight reduction in obese PCOS women, clomifene citrate (CC) is considered the first line treatment for ovulation induction (OI) in these women. 75-80% of women will ovulate after CC administration. However, there is a discrepancy between the ovulation rate and pregnancy rate, which was reported to be 22% per each ovulating cycles after CC. Other alternatives, including gonadotropin injections and laparoscopic ovarian drilling, carried different disadvantages, such as costly treatment and risks of ovarian hyperstimulation syndrome and multiple pregnancy rate in gonadotrophin therapy and surgical risks and risk of ovarian failure in surgical treatment.

The use of aromatase inhibitor, letrozole (LTZ), in reproductive medicine started in 2001. After this publication, there have been many groups of investigators studying the use of LTZ either in OI or ovarian stimulation in IVF cycles. A large multicentre randomized trial reported a significantly higher ovulation rate and live-birth rate comparing LTZ with CC. In majority of the publications, the multiple pregnancy rate was lower in LTZ group than in CC group. This can be attributed to the higher chance of monofollicular development after LTZ compared with CC. However, there is no information comparing the hormonal profile and follicular development after letrozole and CC.

Mild ovarian stimulation using LTZ or CC in conjunction with intrauterine insemination is commonly offered to ovulatory women with unexplained infertility, minimal endometriosis or mild factor to improve the pregnancy rate. There is again no information comparing the hormonal profile and follicular development after letrozole and CC in ovulatory women.

The aim of this study is to compare the hormonal profile after the use of LTZ and CC in anovulatory PCOS women and ovulatory women with unexplained subfertility. The hypothesis is that the FSH risk after LTZ is shorter than that of CC.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 39 Years
Eligibility Inclusion criteria:

- Age of women 18-39 years

- Irregular menstrual cycles with anovulation (cycle >35 days) together with polycystic ovaries on pelvic scanning or laboratory/clinical hyperandrogenism (in PCOS group)

- Regular cycle of 25-35 days cycle for the ovulatory women group

- Body mass index </= 30 kg/m2

Exclusion criteria:

- Couples undergoing ART treatment cycles

- History of ovarian surgery

- Drug allergy to CC or LTZ

- History of diabetes mellitus or other severe medical diseases

- Refusal to join the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Letrozole
Letrozole 2.5 mg daily from Day 2 to 6
Clomiphene
After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary FSH concentrations Alternative day during ovulation induction cycle (for about 3 month) No
Secondary LHconcentration Alternative day during ovulation induction cycles (for about 3 month) No
Secondary Endometrial Thickness Monitoring during ovulation induction cycle (for about 3 month) No
Secondary Oestradiol concentration Alternative day during ovulation induction cycles (for about 3 month) No
Secondary Progesterone concentration Alternative day during ovulation induction cycles (for about 3 month) No
Secondary Number of growing follicles Monitoring during OI cycles (for about 3 month) No
See also
  Status Clinical Trial Phase
Recruiting NCT02244567 - Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women Phase 1
Completed NCT01653743 - Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women Phase 3
Completed NCT01672801 - Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT N/A
Completed NCT00579540 - Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels N/A
Terminated NCT05084274 - Optimising Preconceptual Health in Subfertile PCOS Patients Using a Lifestyle Modification Program N/A
Completed NCT03717935 - Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS N/A
Withdrawn NCT01716429 - Healthy Eating for Reproductive Health: Greenville N/A
Active, not recruiting NCT02896452 - Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
Recruiting NCT05146063 - LNK in Polycystic Ovary Syndrome With Insulin Resistance
Recruiting NCT06303219 - Effects of Traditional Moderate Intensity Training and High Intensity Interval Training in Polycystic Ovarian Syndrome N/A
Completed NCT02869750 - The Relationship Between Adipokines, Obesity and Insulin Resistance in Women With Polycystic Ovarian Syndrome
Completed NCT01237106 - In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT01185704 - Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) Phase 3
Recruiting NCT04029805 - Evaluation of a Combination of a Plant Extract and a Probiotic on Glucidic Metabolism in Women With PCOS and High Insulin Levels Phase 1/Phase 2
Completed NCT01675843 - Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Phase 4
Completed NCT01577017 - The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) Phase 3
Completed NCT00478504 - Letrozole Versus Clomifene Citrate for Ovulation Induction Phase 4
Completed NCT05215223 - Effect of Whole Body Vibration on Insulin Resistance in Females With Polycystic Ovarian Syndrome N/A
Completed NCT03358199 - LOD Before IVF/ICSI in PCOS Patients With High AMH N/A
Completed NCT02436226 - Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS Phase 4